Last reviewed 2026-04-20 · How we verify

Isoprofenamine (CLORPRENALINE)

Phase 2 active Small molecule

Isoprofenamine (generic name: CLORPRENALINE) is a clorprenaline drug. It is currently in Phase 2 development.

Isoprofenamine works by stimulating the beta-2 receptors in the body, leading to bronchodilation and increased airway resistance.

Isoprofenamine, also known as clorprenaline, is a small molecule drug that targets the beta-2 adrenergic receptor. It is classified as a clorprenaline drug, but its current status and indications are unknown. As a beta-2 agonist, it works by stimulating the beta-2 receptors in the body, leading to bronchodilation and increased airway resistance. However, its commercial status, safety considerations, and pharmacokinetic properties are not well-documented. Further research is needed to fully understand its potential therapeutic applications and risks.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLORPRENALINE
Drug class	clorprenaline
Target	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Modality	Small molecule
Therapeutic area	Respiratory
Phase	Phase 2

Mechanism of action

Imagine your airways are like narrow roads. When you breathe, air has to squeeze through these roads. Isoprofenamine helps widen these roads by stimulating the beta-2 receptors, making it easier for air to flow in and out of your lungs.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Isoprofenamine CI brief — competitive landscape report
Isoprofenamine updates RSS · CI watch RSS

Frequently asked questions about Isoprofenamine

What is Isoprofenamine?

Isoprofenamine (CLORPRENALINE) is a clorprenaline drug.

How does Isoprofenamine work?

Isoprofenamine works by stimulating the beta-2 receptors in the body, leading to bronchodilation and increased airway resistance.

What is the generic name of Isoprofenamine?

CLORPRENALINE is the generic (nonproprietary) name of Isoprofenamine.

What drug class is Isoprofenamine in?

Isoprofenamine belongs to the clorprenaline class. See all clorprenaline drugs at /class/clorprenaline.

What development phase is Isoprofenamine in?

Isoprofenamine is in Phase 2.

What does Isoprofenamine target?

Isoprofenamine targets Beta-1 adrenergic receptor, Beta-2 adrenergic receptor and is a clorprenaline.

Drug class: All clorprenaline drugs
Target: All drugs targeting Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Therapeutic area: All drugs in Respiratory

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing